Antibodies against the main immunogenic region of the acetylcholine receptor correlate with disease severity in myasthenia gravis

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 83, Issue 9, 2012, Pages 935-940

  Masuda, Tomoko ^a   Motomura, Masakatsu ^a   Utsugisawa, Kimiaki ^b   Nagane, Yuriko ^b   Nakata, Ruka ^a   Tokuda, Masahiro ^a   Fukuda, Taku ^a   Yoshimura, Toshiro ^a   Tsujihata, Mitsuhiro ^c   Kawakami, Atsushi ^a  

^a NAGASAKI UNIVERSITY   (Japan)

^b General Hanamaki Hospital   (Japan)

^c Nagasaki Kita Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; MAIN IMMUNOGENIC REGION AUTOANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 35; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; BULBAR PARALYSIS; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; GENERALIZED MYASTHENIA GRAVIS; HUMAN; IMMUNOPRECIPITATION; MAJOR CLINICAL STUDY; MALE; MYASTHENIA GRAVIS; OCULAR MYASTHENIA GRAVIS; PREDICTION; PRIORITY JOURNAL; RECEPTOR BINDING; RETROSPECTIVE STUDY; SCORING SYSTEM; THYMOMA;

EID: 84864819393     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2012-302705     Document Type: Article

References (39)

1. Hoch W, McConville J, Helms S, et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001;7:365-8. (Pubitemid 32224355)
2. Higuchi O, Hamuro J, Motomura M, et al. Autoantibodies to LDL receptor-related protein 4 in myasthenia gravis. Ann Neurol 2011;69:418-22.
3. Zhang B, Tzartos JS, Belimezi M, et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol 2012;69:445-51.
4. Wu H, Xiong WC, Mei L. To build a synapse: signaling pathways in neuromuscular junction assembly. Development 2010;137:1017-33.
5. Motomura M. The pathophysiology and treatment of autoimmune neuromuscular junction diseases. Rinsho Shinkeigaku 2011; 51:872-6.
6. Vincent A, Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 1985;48:1246-52. (Pubitemid 16229407)
7. Somnier FE. Clinical implementation of anti-acetylcholine receptor antibodies. J Neurol Neurosurg Psychiatry 1993;56:496-504. (Pubitemid 23171780)
8. Tindall RS. Humoral immunity in myasthenia gravis: biochemical characterization of acquired antireceptor antibodies and clinical correlations. Ann Neurol 1981;10:437-47. (Pubitemid 11029783)
9. Vincent A, Newsom Davis J. Anti-acetylcholine receptor antibodies. J Neurol Neurosurg Psychiatry 1980;43:590-600. (Pubitemid 10059113)
10. Besinger UA, Toyka KV, Hömberg M, et al. Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology 1983;33:1316-21. (Pubitemid 13021194)
11. Howard FM Jr, Lennon VA, Finley J, et al. Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis. Ann N Y Acad Sci 1987;505:526-38.
12. Pachner AR. Anti-acetylcholine receptor antibodies block bungarotoxin binding to native human acetylcholine receptor on the surface of TE671 cells. Neurology 1989;39:1057-61. (Pubitemid 19217473)
13. Bartoccioni E, Scuderi F, Minicuci GM, et al. Anti-MuSK antibodies: correlation with myasthenia gravis severity. Neurology 2006;67:505-7. (Pubitemid 44214984)
14. Sanders DB, El-Salem K, Massey JM, et al. Clinical aspects of MuSK antibody positive seronegative MG. Neurology 2003;60:1978-80. (Pubitemid 36736017)
15. Guptill JT, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve 2011;44:36-40.
16. Shigemoto K, Kubo S, Maruyama N, et al. Induction of myasthenia by immunization against muscle-specific kinase. J Clin Invest 2006;116 :1016-24.
17. Punga AR, Lin S, Oliveri F, et al. Muscle-selective synaptic disassembly and reorganization in MuSK antibody positive MG mice. Exp Neurol 2011; 230:207-17.
18. Tzartos SJ, Lindstrom JM. Monoclonal antibodies used to probe acetylcholine receptor structure: localization of the main immunogenic region and detection of similarities between subunits. Proc Natl Acad Sci U S A 1980;77:755-9. (Pubitemid 10108379)
19. Tzartos S, Hochschwender S, Vasquez P, et al. Passive transfer of experimental autoimmune myasthenia gravis by monoclonal antibodies to the main immunogenic region of the acetylcholine receptor. J Neuroimmunol 1987;15:185-94. (Pubitemid 17075151)
20. Beroukhim R, Unwin N. Three-dimensional location of the main immunogenic region of the acetylcholine receptor. Neuron 1995;15 :323-31.
21. Tzartos SJ, Barkas T, Cung MT, et al. Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor. Immunol Rev 1998;163 :89-120. (Pubitemid 28327864)
22. Luo J, Lindstrom J. Antigenic structure of the human muscle nicotinic acetylcholine receptor main immunogenic region. J Mol Neurosci 2010;40:217-20.
23. Tzartos SJ, Seybold ME, Lindstrom J. Specificity of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies. Proc Natl Acad Sci 1982;79:188-92. (Pubitemid 12181512)
24. Poulas K, Tsouloufis T, Tzartos SJ. Treatment of passively transferred experimental autoimmune myasthenia gravis using papain. Clin Exp Immunol 2000;120:363-8. (Pubitemid 30304235)
25. Lennon VA, McCormick DJ, Lambert EH, et al. Region of peptide 125-147 of acetylcholine receptor alpha subunit is exposed at neuromuscular junction and induces experimental autoimmune myasthenia gravis, T-cell immunity, and modulating autoantibodies. Proc Natl Acad Sci U S A 1985;82:8805-9. (Pubitemid 16101133)
26. Heidenreich F, Vincent A, Willcox N, et al. Anti-acetylcholine receptor antibody specificities in serum and in thymic cell culture supernatants from myasthenia gravis patients. Neurology 1988; 38:1784-8. (Pubitemid 18265048)
27. Brejc K, van Dijk WJ, Klaassen RV, et al. Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors. Nature 2001;411:269-76. (Pubitemid 32467026)
28. Lindstrom JM. Nicotinic acetylcholine receptors of muscles and nerves: comparison of their structures, functional roles, and vulnerability to pathology. Ann N Y Acad Sci 2003;998:41-52. (Pubitemid 37194146)
29. Luo J, Taylor P, Losen M, et al. Main immunogenic region structure promotes binding of conformation-dependent myasthenia gravis autoantibodies, nicotinic acetylcholine receptor conformation maturation, and agonist sensitivity. J Neurosci 2009;29:13898-908.
30. Kusner LL, Puwanant A, Kaminski HJ. Ocular myasthenia: diagnosis, treatment, and pathogenesis. Neurologist 2006;12 :231-9. (Pubitemid 44440016)
31. Bever CT Jr, Aquino AV, Penn AS, et al. Prognosis of ocular myasthenia. Ann Neurol 1983;14:516-19. (Pubitemid 14239718)
32. Oosterhuis HJ. The natural course of myasthenia gravis: a long term follow up study. J Neurol Neurosurg Psychiatry 1989;52 :1121-7. (Pubitemid 19255673)
33. Lecky BR, Morgan-Hughes JA, Landon DN, et al. Intercostal muscle acetylcholine receptors in longstanding ocular myasthenia. Lancet 1980;2 :1311-12.
34. Tsujihata M, Yoshimura T, Satoh A, et al. Diagnostic significance of IgG, C3, and C9 at the limb muscle motor end-plate in minimal myasthenia gravis. Neurology 1989;39:1359-63. (Pubitemid 19246812)
35. Shiraisi H, Motomura M, Yoshimura T, et al. Acetylcholine receptor loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol 2005;57:289-93. (Pubitemid 40179868)
36. Oda K. Differences in acetylcholine receptor-antibody interactions between extraocular and extremity muscle fibers. Ann N Y Acad Sci 1993;681:238-55. (Pubitemid 23233826)
37. Kaminski HJ, Li Z, Richmonds C, et al. Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis. Exp Neurol 2004;189:333-42. (Pubitemid 39221825)
38. Tsujihata M, Hazama R, Ishii N, et al. Limb muscle endplates in ocular myasthenia gravis: quantitative ultrastructural study. Neurology 1979;29:654-61. (Pubitemid 9135466)
39. Soltys J, Gong B, Kaminski HJ, et al. Extraocular muscle susceptibility to myasthenia gravis: unique immunological environment? Ann N Y Acad Sci 2008;1132:220-4. (Pubitemid 351841377)